Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | PRKCA | P17252 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6507440 | 0.92 | ATM (0.57) | ATMALOX5SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL6499620 | 0.89 | ATM (0.54) | ATMALOX5SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL6503786 | 0.89 | ATM (0.54) | ATMALOX5SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL6506787 | 0.86 | ATM (0.51) | ATMALOX5SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL242325 | 0.85 | ATM (0.57) | ATMALOX5SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL14879672 | 0.84 | ATM (0.56) | ATMALOX5SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL382520 | 0.84 | TDP1 (0.54) | SMN1; SMN2ALDH1A1LMNATDP1MAPK1 | |
| SCHEMBL7658812 | 0.84 | TDP1 (0.54) | SMN1; SMN2ALDH1A1LMNATDP1MAPK1 | |
| SCHEMBL14637591 | 0.84 | TDP1 (0.54) | SMN1; SMN2ALDH1A1LMNATDP1MAPK1 | |
| SCHEMBL6501171 | 0.84 | ATM (0.56) | ATMALOX5SMN1; SMN2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234355-A1 | ISOQUINOLINE DERIVATIVES AND THEIR USE AS INHIBITORS OF CYTOKINE MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2010-09-16 | — | — | US | disclosed |
| CN-101506171-A | Isoquinoline derivatives as inhibitors of cytokine mediated diseases and uses thereof | ASTRAZENECA AB (SE) | 2009-08-12 | — | — | CN | disclosed |
| US-20080207596-A1 | Novel compounds 329 | MARTIN BARRIE | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207596-A1 | Novel compounds 329 | CCL11, IL2, IL1B | ATM 2448/4885ALOX5 2399/4885SMN1; SMN2 1472/4885 |
| US-20100234355-A1 | ISOQUINOLINE DERIVATIVES AND THEIR USE AS INHIBITORS OF CYTOKINE MEDIATED DISEASES | IL2, IFNG, IL1B | ATM 1240/4885ALOX5 2021/4885SMN1; SMN2 2485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.